We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Fresenius SE and Company KGaA (PK) | USOTC:FSNUY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.112 | -1.48% | 7.4405 | 7.32 | 7.63 | 7.53 | 7.4405 | 7.53 | 44,836 | 21:23:30 |
By Mauro Orru
Fresenius SE & Co. said Thursday that net income before special items for the third quarter fell, while sales rose slightly, and backed its 2020 outlook.
The German health-care company said net income before special items fell 4% to 427 million euros ($501.6 million), beating a Vara Research consensus of EUR418 million.
Earnings before interest and taxes before special items for the quarter fell 3% to EUR1.11 billion, 1% ahead of consensus.
Sales rose 1% to EUR8.92 billion compared with consensus of EUR8.88 billion.
Fresenius said the coronavirus pandemic would continue to harm operations in the fourth quarter, but backed its guidance for 2020 sales growth between 3% to 6% at constant currencies and for net income to fall up to 4% or rise up to 1% at constant currencies.
At Fresenius Medical Care AG & Co, the company's dialysis division, third-quarter net profit rose to EUR354 million from EUR333 million, while revenue remained largely flat at EUR4.41 billion.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
October 29, 2020 02:31 ET (06:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Fresenius SE and Company... (PK) Chart |
1 Month Fresenius SE and Company... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions